ADVANCED MEDICAL SOLUTIONS GROUP PLC Financials Advanced Medical Solutions Group plc
Equities
AMS
GB0004536594
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 185.8 GBX | -0.43% |
|
+1.20% | -10.46% |
| Mar. 28 | Aviva and L&G cut; mixed calls on Diploma | AN |
| Mar. 13 | Advanced Medical 2023 profit falls; buys Peters Surgical | AN |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 587.1 | 636.1 | 523.4 | 730.3 | 561.5 | 403.8 | 403.8 | - |
| Enterprise Value (EV) 1 | 510.7 | 571.3 | 480.7 | 667.2 | 489 | 390.8 | 416.1 | 412.8 |
| P/E ratio | 26.2 x | 33.9 x | 61.7 x | 42.2 x | 27.8 x | 28.6 x | 40.9 x | 22.9 x |
| Yield | 0.48% | 0.52% | 0.7% | 0.58% | 0.83% | 1.14% | 1.41% | 1.6% |
| Capitalization / Revenue | 5.72 x | 6.21 x | 6.03 x | 6.72 x | 4.52 x | 3.57 x | 2.26 x | 1.74 x |
| EV / Revenue | 4.98 x | 5.58 x | 5.54 x | 6.14 x | 3.93 x | 3.1 x | 2.33 x | 1.78 x |
| EV / EBITDA | 16.5 x | 18.7 x | 26.8 x | 21.7 x | 14.6 x | 13.2 x | 11.1 x | 8.5 x |
| EV / FCF | 29.5 x | 30 x | 25.1 x | 22.8 x | 21.1 x | 44.4 x | -26.3 x | 13.7 x |
| FCF Yield | 3.39% | 3.33% | 3.99% | 4.38% | 4.73% | 2.25% | -3.81% | 7.32% |
| Price to Book | 3.39 x | 3.32 x | 2.62 x | 3.48 x | 2.4 x | 1.86 x | 1.61 x | 1.54 x |
| Nbr of stocks (in thousands) | 213,479 | 214,891 | 215,384 | 216,071 | 216,793 | 217,341 | 217,341 | - |
| Reference price 2 | 2.750 | 2.960 | 2.430 | 3.380 | 2.590 | 1.858 | 1.858 | 1.858 |
| Announcement Date | 3/13/19 | 3/11/20 | 3/17/21 | 3/16/22 | 3/15/23 | 3/13/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 102.6 | 102.4 | 86.8 | 108.6 | 124.3 | 126.2 | 178.3 | 231.8 |
| EBITDA 1 | 30.86 | 30.62 | 17.92 | 30.79 | 33.48 | 29.68 | 37.34 | 48.56 |
| EBIT 1 | 28.7 | 27.46 | 14.45 | 26.9 | 29.43 | 25.3 | 27.44 | 37.72 |
| Operating Margin | 27.98% | 26.83% | 16.65% | 24.77% | 23.67% | 20.05% | 15.39% | 16.27% |
| Earnings before Tax (EBT) 1 | 28.43 | 24.26 | 10.09 | 21.98 | 25.91 | 21.16 | 15.33 | 25.4 |
| Net income 1 | 22.65 | 18.92 | 8.584 | 17.48 | 20.41 | 15.89 | 9.775 | 17.7 |
| Net margin | 22.08% | 18.48% | 9.89% | 16.1% | 16.41% | 12.59% | 5.48% | 7.64% |
| EPS 2 | 0.1048 | 0.0872 | 0.0394 | 0.0801 | 0.0930 | 0.0725 | 0.0454 | 0.0810 |
| Free Cash Flow 1 | 17.34 | 19.03 | 19.16 | 29.26 | 23.14 | 8.801 | -15.85 | 30.21 |
| FCF margin | 16.9% | 18.59% | 22.08% | 26.94% | 18.61% | 6.97% | -8.89% | 13.03% |
| FCF Conversion (EBITDA) | 56.18% | 62.14% | 106.96% | 95.02% | 69.1% | 29.66% | - | 62.21% |
| FCF Conversion (Net income) | 76.54% | 100.57% | 223.26% | 167.36% | 113.39% | 55.39% | - | 170.69% |
| Dividend per Share 2 | 0.0132 | 0.0155 | 0.0170 | 0.0195 | 0.0215 | 0.0236 | 0.0262 | 0.0297 |
| Announcement Date | 3/13/19 | 3/11/20 | 3/17/21 | 3/16/22 | 3/15/23 | 3/13/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 48.71 | - | 39.28 | - | - | 58.4 | 58.3 | 63.09 | 63.12 |
| EBITDA | 13.67 | - | - | - | - | 15.86 | - | 23.85 | 14.21 |
| EBIT 1 | - | - | 5.5 | - | - | 13.91 | 12.24 | 13.43 | 11.88 |
| Operating Margin | - | - | 14% | - | - | 23.82% | 20.99% | 21.28% | 18.81% |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | 10.79 | - | 11.77 | 9.389 |
| Net income | - | - | - | - | 8.932 | 8.549 | - | - | - |
| Net margin | - | - | - | - | - | 14.64% | - | - | - |
| EPS | - | - | - | - | 0.0410 | 0.0391 | - | - | - |
| Dividend per Share 2 | - | 0.0105 | - | 0.0120 | - | 0.0137 | - | 0.007000 | 0.0166 |
| Announcement Date | 9/11/19 | 3/11/20 | 9/16/20 | 3/17/21 | 9/15/21 | 3/16/22 | 9/14/22 | 9/20/23 | 3/13/24 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 12.3 | 8.95 |
| Net Cash position 1 | 76.4 | 64.8 | 42.7 | 63.1 | 72.5 | 60.2 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | 0.3296 x | 0.1843 x |
| Free Cash Flow 1 | 17.3 | 19 | 19.2 | 29.3 | 23.1 | 8.8 | -15.8 | 30.2 |
| ROE (net income / shareholders' equity) | 13.9% | 10.4% | 4.36% | 8.43% | 9.08% | 8.56% | 9.6% | 11% |
| ROA (Net income/ Total Assets) | 12.4% | 8.75% | 3.69% | 7.16% | 7.69% | 5.57% | - | - |
| Assets 1 | 182.1 | 216.1 | 232.8 | 244 | 265.3 | 285.1 | - | - |
| Book Value Per Share 2 | 0.8100 | 0.8900 | 0.9300 | 0.9700 | 1.080 | 1.110 | 1.150 | 1.210 |
| Cash Flow per Share 2 | 0.0900 | 0.1000 | 0.1000 | 0.1400 | 0.1200 | 0.0600 | 0.1300 | 0.1800 |
| Capex 1 | 3.06 | 2.67 | 2.35 | 1.77 | 3.74 | 3.54 | 5.33 | 5 |
| Capex / Sales | 2.98% | 2.61% | 2.7% | 1.63% | 3.01% | 2.81% | 2.99% | 2.16% |
| Announcement Date | 3/13/19 | 3/11/20 | 3/17/21 | 3/16/22 | 3/15/23 | 3/13/24 | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1.858
GBP
Average target price
2.522
GBP
Spread / Average Target
+35.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.46% | 503M | |
| +11.84% | 27.79B | |
| -32.98% | 2.98B | |
| -15.97% | 2.52B | |
| +11.90% | 2.34B | |
| -1.11% | 1.91B | |
| -13.37% | 1.83B | |
| -7.78% | 1.39B | |
| -0.38% | 1.27B | |
| +13.51% | 1.12B |
- Stock Market
- Equities
- AMS Stock
- Financials Advanced Medical Solutions Group plc
